- Home
- INFY vs IQV Comparison
INFY vs IQV Comparison
Compare INFY & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INFY | IQV |
|---|---|---|
| Founded | 1981 | 1982 |
| Country | India | United States |
| Employees | 325000 | 93000 |
| Industry | EDP Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6B | 43.1B |
| IPO Year | 1999 | 2013 |
Fundamental Metrics
Financial Performance| Metric | INFY | IQV |
|---|---|---|
| Price | $12.77 | $264.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 20 |
| Target Price | $12.07 | ★ $311.89 |
| AVG Volume (30 Days) | ★ 21.8M | 1.2M |
| Earning Date | 10-23-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 5.24 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $9.17 | $7.18 |
| Revenue Next Year | $3.25 | $6.34 |
| P/E Ratio | ★ $19.11 | $50.37 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $10.12 | $154.50 |
| 52 Week High | $30.00 | $284.50 |
Technical Indicators
Market Signals| Indicator | INFY | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 46.93 |
| Support Level | $11.65 | $252.55 |
| Resistance Level | $12.63 | $276.99 |
| Average True Range (ATR) | 0.38 | 10.38 |
| MACD | -0.03 | -1.50 |
| Stochastic Oscillator | 26.60 | 35.53 |
Price Performance
Historical ComparisonAbout INFY Infosys Limited
Infosys is an IT services provider based in Bengaluru, India, with offices in more than 50 countries. The company leverages its offshore outsourcing model to serve clients across different industries, such as financial services and manufacturing. Infosys' IT services offerings include consulting, digital transformation, and business process outsourcing.
About IQV IQVIA Holdings Inc.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.